Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.37 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | SELL | P14151 | 1/20 | 0.33 |
| ▸ | SELP | P16109 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10188789 | 0.82 | FBP1 (0.49) | P2RY14FBP1 | |
| SCHEMBL1104569 | 0.82 | SMPD1 (0.45) | — | |
| SCHEMBL412751 | 0.76 | FBP1 (0.42) | P2RY14FBP1 | |
| SCHEMBL13071418 | 0.75 | FBP1 (0.41) | P2RY14FBP1 | |
| SCHEMBL17945370 | 0.75 | AMY1A (0.33) | AMY1AFBP1 | |
| SCHEMBL14985207 | 0.74 | P2RY14 (0.58) | P2RY14B4GALT1 | |
| SCHEMBL17945414 | 0.74 | AMY1A (0.32) | AMY1AFBP1 | |
| SCHEMBL27950156 | 0.72 | SMPD1 (0.43) | — | |
| SCHEMBL9218827 | 0.72 | P2RY14 (0.43) | P2RY14B4GALT1 | |
| SCHEMBL23563168 | 0.71 | ITPR3 (0.45) | P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153725-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100234528-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234528-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | AMY1A 1333/4885P2RY14 4297/4885SELE 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.